Warning Letter — Olympus Medical Systems Corporation
The FDA issued a Warning Letter to Olympus Medical Systems Corporation on October 7, 2026, following an evaluation by the Center for Devices and Radiological Health (CDRH).
This notice affects Olympus Medical Systems Corporation, specifically its regulatory, quality, and compliance departments responsible for oversight of medical device manufacturing and reporting.
The issuance of a Warning Letter by CDRH indicates significant regulatory non-compliance that was likely not resolved during the initial inspection phase. This represents an escalated enforcement action that could lead to further restrictions, such as the withholding of device approvals or import alerts, if the underlying quality system or reporting issues are not remediated to the agency's satisfaction.
Quality and regulatory teams should perform a comprehensive review of internal auditing procedures and documentation to ensure all observations are addressed. Verify that post-market surveillance and reporting workflows are meeting the specific timelines and formatting requirements dictated by the Center for Devices and Radiological Health.
FDA Warning Letter issued to: Olympus Medical Systems Corporation. 10/07/2026 — Center for Devices and Radiological Health. Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/olympus-medical-systems-corporation-729208-10072026
Open in openFDA / FDA.gov